{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:55Z","timestamp":1753892995330,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Confinement conditions in prison communities are associated with increased susceptibility to infectious outbreaks. The COVID-19 pandemic has been characterized by high transmissibility and clinical severity resulting in a high number of infections and deaths worldwide. Vaccination has been a crucial tool in mitigating its devastating effects. The aim of this study is to asses the prevalence of antibodies against the Spike protein of SARS-CoV-2 in vaccinated prisoners and staff at a specific prison in Alicante.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional epidemiological study was designed for the population in scope using a rapid lateral flow immunochromatography serological test, conducted on July 27, 2023. Demographic and clinical variables were collected through a questionnaire. Statistical analysis was performed using the SPSS 29.0 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 560 people participated in the study; the predominant profile was men (77.3%) with an average age of 45.7\u202fyears. 71.4% of subjects were prisoners and 28.6% were prison staff. Regarding the detection of anti-SARS-CoV-2 antibodies obtained through serological test, 60.9% of the sample gave a positive result. 69.1% of participants received the last dose in 2022 or later and 62.2% received booster doses. The vaccines administered in the last dose were Biontech\/Pfizer and Moderna in 88.6% of the cases. 59.5% of sample had suffered from COVID-19 and 67.0% did not have any clinical comorbidity. In the regression analysis, it was observed that the variables with a stronger statistical relationship with presence of anti-SARS-CoV-2 antibodies were: the number of years since last vaccine dose was received (aOR: 0.08; 95%CI: 0.05; 0.16) the number of vaccine doses received (aOR: 4.8; 95%CI: 2.9; 8.0) and presenting any comorbidity (aOR: 4.3; 95%CI: 2.4; 8.0). The staff received more booster doses and obtained a better response to seropositivity, with 72.5% of anti-SARS-CoV-2 result positive while prisoners reached 56.3%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The COVID-19 vaccination status within the prison community following the initiation of primary immunization and subsequent booster doses, shows a low immunization coverage (60.9%), which is below expectations given the immunization strategies implemented since the start of the pandemic. There are notable differences in vaccination rates between prison staff and prisoners. These disparities are concerning, and authorities responsible for prison public health should take a more proactive approach to ensuring vaccination among prisoners.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1490809","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:41:38Z","timestamp":1738046498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)"],"prefix":"10.3389","volume":"13","author":[{"given":"Ana C.","family":"Montagud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Moragues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Vicente-Alcalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Montagud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Hurtado-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Tuells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e026806","DOI":"10.1136\/bmjopen-2018-026806","article-title":"Prison cell spatial density and infectious and communicable diseases: a systematic review","volume":"9","author":"Simpson","year":"2019","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1186\/s12889-021-11077-0","article-title":"Risk of COVID-19 infection among prison staff in the United States","volume":"21","author":"Nowotny","year":"2021","journal-title":"BMC Public Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2105\/AJPH.2021.306206","article-title":"Essential strategies to curb COVID-19 transmission in prisons and jails","volume":"111","author":"Macmadu","year":"2021","journal-title":"Am J Public Health"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2020.12528","article-title":"COVID-19 cases and deaths in federal and state prisons","volume":"324","author":"Saloner","year":"2020","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14745\/ccdr.v47i01a10","article-title":"A time-series analysis of testing and COVID-19 outbreaks in Canadian federal prisons to inform","volume":"47","author":"Blair","year":"2021","journal-title":"Can Commun Dis Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.puhe.2023.02.013","article-title":"COVID-19 pandemic in prisons in Spain: characteristics of cases and implemented control measures, March 2020\u2013June 2022","volume":"218","author":"Hernando","year":"2023","journal-title":"Public Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"806438","DOI":"10.3389\/fmed.2022.806438","article-title":"Control of a COVID-19 outbreak in a Spanish prison: lessons learned in outbreak control","volume":"9","author":"Vicente-Alcalde","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e0267070","DOI":"10.1371\/journal.pone.0267070","article-title":"COVID-19 vaccine for people who live and work in prisons worldwide: a scoping review","volume":"17","author":"Ismail","year":"2022","journal-title":"PLoS One"},{"year":"2021","key":"ref9"},{"year":"2021","key":"ref10"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"13725","DOI":"10.3390\/ijerph192113725","article-title":"COVID-19-infections and immunization of inmates in penitentiary institutions in Poland in 2021","volume":"19","author":"Augustynowicz","year":"2022","journal-title":"Int J Environ Res Public Health"},{"year":"2021","key":"ref12"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/healthcare10020282","article-title":"Health Management in Italian Prisons during COVID-19 outbreak: a focus on the second and third wave","volume":"10","author":"Vella","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.3390\/ijerph17207589","article-title":"Vaccination coverage among prisoners: a systematic review","volume":"17","author":"Vicente-Alcalde","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.3390\/ijerph17218045","article-title":"Immunization coverage of inmates in Spanish prisons","volume":"17","author":"Vicente-Alcalde","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3390\/vaccines11071237","article-title":"COVID-19 vaccine refusal and medical distrust held by correctional officers","volume":"11","author":"Kerrison","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.jvacx.2022.100150","article-title":"Barriers and facilitators to COVID-19 vaccine acceptability among people incarcerated in Canadian federal prisons: a qualitative study","volume":"10","author":"Lessard","year":"2022","journal-title":"Vaccine X"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0264145","DOI":"10.1371\/journal.pone.0264145","article-title":"Reasons for COVID-19 vaccine refusal among people incarcerated in Canadian federal prisons","volume":"17","author":"Ortiz-Paredes","year":"2022","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJMc2105282","article-title":"COVID-19 vaccine acceptance in California state prisons","volume":"385","author":"Chin","year":"2021","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3390\/vaccines11061081","article-title":"COVID-19 vaccination status as well as factors associated with COVID-19 vaccine acceptance and hesitancy among prisoners and the implications","volume":"11","author":"Shabir","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40352-023-00240-x","article-title":"Facilitators and barriers to COVID-19 vaccination among incarcerated people and staff in three large, state prisons: a cross-sectional study","volume":"11","author":"Osman","year":"2023","journal-title":"Health Justice"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1016\/j.vaccine.2023.09.045","article-title":"Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails","volume":"41","author":"Cassarino","year":"2023","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3390\/vaccines11101547","article-title":"Acceptance of the COVID-19 vaccine by prisoners and staff in Spanish prisons","volume":"11","author":"Vicente-Alcalde","year":"2023","journal-title":"Vaccines (Basel)"},{"year":"2021","key":"ref24"},{"year":"2021","key":"ref25"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e44684","DOI":"10.7759\/cureus.44684","article-title":"COVID-19 infection rates in vaccinated and unvaccinated inmates: a retrospective cohort study","volume":"15","author":"Ko","year":"2023","journal-title":"Cureus"},{"key":"ref28","first-page":"e202312111","article-title":"Vacunaci\u00f3n contra la COVID-19 en la Universidad de Alicante (Espa\u00f1a): detecci\u00f3n de anticuerpos neutralizantes frente al sars-CoV-2 mediante test serol\u00f3gico r\u00e1pido, un estudio transversal [COVID-19 vaccination at the University of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study]","volume":"97","author":"Montagud","year":"2023","journal-title":"Rev Esp Salud Publica"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.rce.2024.01.009","article-title":"Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer\u2013BioNTech) en trabajadores sanitarios [Prevalence of generated neutralizing antibodies against SARS-CoV-2 after two doses of BNT162b2 (Pfizer\u2013BioNTech) vaccine in health staffs]","volume":"224","author":"Montagud","year":"2024","journal-title":"Rev Clin Esp"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/diagnostics12061388","article-title":"Performance of antigen detection tests for SARS-CoV-2: a systematic review and Meta-analysis","volume":"12","author":"Tapari","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3390\/ijerph18041908","article-title":"Seroprevalence study and cross-sectional survey on COVID-19 for a plan to reopen the University of Alicante (Spain)","volume":"18","author":"Tuells","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/vaccines10040510","article-title":"Detection of neutralizing antibodies against SARS-CoV-2 post-vaccination in health care staffs of a large tertiary hospital in Spain by using a rapid test LFIC and sVNT-ELISA","volume":"10","author":"Tuells","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"10s","DOI":"10.11606\/s1518-8787.2023057004717","article-title":"Overview of SARS-COV-2 infection at the Butantan penitentiary progression center","volume":"57","author":"Andrade","year":"2023","journal-title":"Rev Saude Publica"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1108\/IJPH-01-2022-0002","article-title":"SARS-CoV-2 seroprevalence study after the first wave among persons living and working in an overcrowded Swiss prison","volume":"19","author":"G\u00e9taz","year":"2022","journal-title":"Int J Prison Health"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1093\/cid\/ciac031","article-title":"Seroprevalence and risk factors for severe acute respiratory syndrome coronavirus 2 among incarcerated adult men in Quebec, Canada, 2021","volume":"75","author":"Kronfli","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1323195","DOI":"10.3389\/fpubh.2024.1323195","article-title":"Vaccination against emerging and reemerging infectious diseases in places of detention: a global multistage scoping review","volume":"12","author":"Moazen","year":"2024","journal-title":"Front Public Health"},{"key":"ref37","first-page":"1003","article-title":"The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model","volume-title":"BMC Public Health","author":"CV","year":"2022"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/vaccines10071137","article-title":"COVID-19 outbreak and BNT162b2 mRNA vaccination coverage in a correctional facility during circulation of the SARS-CoV-2 omicron BA1 variant in Italy","volume":"10","author":"Stufano","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e149187","DOI":"10.1172\/jci.insight.149187","article-title":"SARS-CoV-2 vaccines: a triumph of science and collaboration","volume":"6","author":"Golob","year":"2021","journal-title":"JCI Insight"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1080\/21645515.2021.1923350","article-title":"Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies","volume":"17","author":"Sharun","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1104124","DOI":"10.3389\/fimmu.2023.1104124","article-title":"Neutralizing antibodies to omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters","volume":"14","author":"Rescigno","year":"2023","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2153537","DOI":"10.1080\/21645515.2022.2153537","article-title":"Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility","volume":"18","author":"Trombetta","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e02005","DOI":"10.1128\/JCM.02005-20","article-title":"Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients","volume":"58","author":"Luchsinger","year":"2020","journal-title":"J Clin Microbiol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1490809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:41:42Z","timestamp":1738046502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1490809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":43,"alternative-id":["10.3389\/fpubh.2025.1490809"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1490809","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"article-number":"1490809"}}